Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Genomic Vision Raises EUR 4 Million in Series B Financing

Abstract:
Genomic Vision, a developer of novel diagnostic and drug discovery solutions based on its world-leading nanotechnology for DNA analysis in the areas of cancer and acute diseases, announced today that it has raised EUR 4 million (approx. USD 6.3 million) in a series B financing round. New investor Vesalius BioCapital joined existing investor Societe Generale Asset Management Alternative Investments (SGAM AI). This round brings the total capital invested to EUR 6 million since Genomic Vision's creation in July 2004.

Genomic Vision Raises EUR 4 Million in Series B Financing

PARIS, France | Posted on July 24th, 2008

The funds will be used to expand Genomic Vision's in-house R&D programs and automation, as well as strengthen the firm's ongoing collaborative programs with partners. "We are delighted to work with financial partners who fully understand and stay informed about our diagnostic and drug discovery activities in the areas of cancer and genetic diseases," said Aaron Bensimon, founder, president and CEO of Genomic Vision. "It is particularly rewarding to have SGAM AI renew their confidence in us after investing three years ago. We are pleased to have attracted Vesalius BioCapital, biotechnology entrepreneurial specialists whose skill and experience will be very useful. This support from our investors will help us to develop our products and services more quickly and enable us to take advantage of growing market opportunities."

"Genomic Vision has a unique technology, Molecular Combing, capable of revolutionizing several diagnostic approaches and DNA analysis," said Jean-Yves Nothias, Managing Partner, BioConvergence team of SGAM AI. "We believe very strongly that their genomic tests will be useful for cancers, genetic diseases, viral diseases and many other applications with wide potential markets."

"We are excited about Genomic Vision's capabilities, which have a significant potential to complete the technical developments required for the use of its molecular combing technology for early cancer diagnosis," said Stéphane Verdood, Partner of Vesalius BioCapital.

In a move to enhance the company's development, Genomic Vision recently transferred its operations to Paris Santé Cochin, an innovative healthcare Biotech Park, reputed for its excellent working conditions for early stage biotech firms around the Paris region. Genomic Vision now employs 15 people, carries out its operations in 600m2 (6000 sq ft approx), and benefits from the support and know-how of the Paris Biotech Santé network. Legal advisors for the fund raising were Philippe Simon, KGA, representing Genomic Vision, Hubert Segain from Herbert Smith representing Vesalius BioCapital Venture, and Mickael Lévy representing SGAM AI.

About Genomic Vision Genomic Vision develops novel diagnostic and drug discovery solutions based on its world-leading nanotechnology for DNA analysis in the areas of cancer and acute diseases. The company uses a powerful technique, Molecular Combing Technology, for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. Genomic Vision holds an exclusive license for the technology from the Pasteur Institute.

Genomic Vision works through partnerships and alliances with the diagnostic and pharmaceutical industries to distribute its tests and services. The company is focused on three key areas: - Diagnostics: the discovery of genomic biomarkers and the development of DNA-based diagnostic tests for early disease identification and management - Drug Development: exploiting the Combing Replication Assay to test the efficacy of lead compounds by studying DNA replication in proliferating cancer cells - Drug Response Biomarkers: the analysis and identification of the genomic region in the human genome to allow the characterization of genetic differences between individuals who respond differently to the same drug

####

About Genomic Vision
Genomic Vision's headquarters and biological research facilities are Paris Santé Cochin, France. The company is supported by a network of collaborations with leading academic researchers and clinicians. The company has raised EUR 6 since its creation in 2004.

For more information, please click here

Contacts:
Andrew Lloyd & Associates
Andrew Lloyd / Neil Hunter
Tel: +44 1273 675100
/


Upesh Mistry
ANDREW LLOYD & ASSOCIATES www.ala.com


Brighton Business Centre
95 Ditchling Road
Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100
Fax: +44 1273 675400

55 rue Boissonade
75014 Paris FRANCE
Tel: +33 1 56 54 07 00
Fax: +33 1 56 54 07 01

Copyright © Genomic Vision

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Imec Reports Four Percent Growth for 2013 Fiscal Year End —Continues to Accelerate Innovation Through Global Collaborations and Technological Breakthroughs in Nanoelectronics— April 24th, 2014

Multicapacity Microreactor for Catalyst Characterisation April 24th, 2014

Making graphene work for real-world devices: Fundamental research in phonon scattering helps researchers design graphene materials for applications April 24th, 2014

Return on investment for kit and promotion materials April 24th, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Premier Healthcare Pitch Competition comes to Atlanta this May April 12th, 2014

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanomedicine

Return on investment for kit and promotion materials April 24th, 2014

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014

Announcements

Imec Reports Four Percent Growth for 2013 Fiscal Year End —Continues to Accelerate Innovation Through Global Collaborations and Technological Breakthroughs in Nanoelectronics— April 24th, 2014

Multicapacity Microreactor for Catalyst Characterisation April 24th, 2014

Making graphene work for real-world devices: Fundamental research in phonon scattering helps researchers design graphene materials for applications April 24th, 2014

Return on investment for kit and promotion materials April 24th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE